OVERVIEW

GHK‑Cu (2 mg × 60 Capsules), also known as copper tripeptide, is a small peptide complex composed of glycyl‑histidyl‑lysine bound to a copper ion. It naturally occurs in human plasma, saliva, and urine and plays roles in wound healing, tissue remodeling, and antioxidant defense. GHK‑Cu has been studied extensively in dermatological and regenerative research for its ability to stimulate collagen and elastin production, support extracellular matrix synthesis, and modulate inflammatory signalling. In laboratory and early clinical studies, it has shown promise in improving skin firmness, reducing fine lines and wrinkles, and enhancing overall skin texture when used in cosmetic or topical formulations. When formulated in oral capsules, the idea is to support systemic pathways linked to tissue repair and antioxidant activity, although most clinical evidence focuses on topical rather than oral use.

Despite its popularity in skincare and wellness communities, GHK‑Cu capsules are not approved by the U.S. Food and Drug Administration as a drug for specific medical conditions, and oral supplementation remains an area of emerging research rather than established therapy. Although some small studies and cosmetic research support its potential benefits for skin and connective tissue, robust evidence from large, controlled clinical trials is limited. Products sold as capsules may vary in purity and quality, as they are typically marketed as nutritional or cosmetic supplements rather than regulated pharmaceuticals. Individuals interested in peptide supplements should consult qualified healthcare professionals, especially if they have underlying health conditions or are taking other medications, and should rely on evidence‑based treatments where available.